BB Biotech’s MEDIVATION, INC. MDVN Stock Holding History

BB Biotech’s Portfolio MDVN Stock Details MDVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,991,112	Closed	-$120M	–	31
2016 Q2	$120M	Sell	1,991,112 -590,000	-23%	-$33.5M	4.74%	9
2016 Q1	$119M	Hold	2,581,112	–	–	4.72%	8
2015 Q4	$125M	Hold	2,581,112	–	–	3.51%	10
2015 Q3	$110M	Hold	2,581,112	–	–	3.48%	10
2015 Q2	$147M	Buy	2,581,112 +31,700	+1%	+$1.95M	4%	9
2015 Q1	$165M	Sell	2,549,412 -220,000	-8%	-$12.6M	4.9%	6
2014 Q4	$138M	Sell	2,769,412 -90,000	-3%	-$4.68M	4.47%	7
2014 Q3	$141M	Sell	2,859,412 -140,000	-5%	-$5.95M	5.75%	6
2014 Q2	$116M	Buy	2,999,412 +80,000	+3%	+$2.7M	5.49%	6
2014 Q1	$94M	Sell	2,919,412 -40,000	-1%	-$1.48M	4.84%	7
2013 Q4	$94.4M	Buy	2,959,412 +60,000	+2%	+$1.81M	5.05%	7
2013 Q3	$86.9M	Hold	2,899,412	–	–	4.73%	7
2013 Q2	$71.3M	Buy	+2,899,412	New	+$73M	5.14%	7

Other funds holding MDVN

GLAM

Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Analytic Investors Los Angeles, California $8.93B AUM 13.54% 1-Year Est. Return

Harvest Management New York $206M AUM 95.44% 1-Year Est. Return

LIM

Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $30.9B AUM 29.72% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return

BB Biotech's MDVN Position: Q3 2016 in Review

BB Biotech sold out of MEDIVATION, INC. (MDVN) in Q3 2016, closing a stake of 1,991,112 shares — an estimated $120M sold.

BB Biotech first reported a position in MDVN in Q2 2013 and held it in 13 quarters. The position peaked at $165M in Q1 2015. 53 funds tracked by Wall St. Rank hold MDVN as of Q3 2016.

BB Biotech reported no remaining MEDIVATION, INC. position as of Q3 2016 after selling out during the quarter.
BB Biotech sold 1,991,112 MEDIVATION, INC. shares in Q3 2016, an estimated $120M.
BB Biotech first reported a position in MEDIVATION, INC. in Q2 2013 and held it in 13 quarters.
BB Biotech's MEDIVATION, INC. position peaked at $165M in Q1 2015.
53 funds tracked by Wall St. Rank held MEDIVATION, INC. as of Q3 2016.

Based on BB Biotech's 13F filing for Q3 2016, filed 10 Nov 2016.